Poxel Raises €13 million to Progress Imeglimin Development to Treat Type 2 diabetes
Poxel S.A. /
Poxel Raises €13 million to Progress Imeglimin Development to Treat Type 2
diabetes
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Lyon, France, December 18, 2012 - Poxel SA announces today, that it has raised
€13 million (USD 17 million) in a Series B round. The financing was led by
Edmond de Rothschild Investment Partners (EdRIP) and included all existing
investors: InnoBio fund managed by CDC Entreprises within FSI France Investment
program; and Omnes Capital (formerly Crédit Agricole Private Equity). A
significant part of the funds will be used to confirm efficacy data of the
company's lead program, Imeglimin, a novel anti-diabetic agent.
Imeglimin is the first in a new Tetrahydrotriazine-containing class of oral
anti-diabetics, the Glimins. It has already demonstrated efficacy and safety in
clinical proof-of-concept trials. Imeglimin is being developed through phase II
trials as a monotherapy and as an add-on therapy to the main anti-diabetic
agents, starting with metformin and sitagliptin. Encouraged by recent positive
data from 2 phase II combination trials that showed significant benefit for
patients, the company now plans to strengthen Imeglimin's efficacy profile as a
monotherapy treatment in a large six-month trial involving 400 diabetic
patients.
Imeglimin has a mitochondrian-based mechanism of action, targeting the
respiratory chain. Through this new mechanism, Imeglimin acts on the three key
defects of Type 2 diabetes, inhibiting hepatic gluconeogenesis, increasing
muscle glucose uptake and restoring normal insulin secretion.
Poxel has further promising anti-diabetic programs in early development,
including a new class of direct AMPK activator. Poxel was founded as spin off
from Merck Serono and in 2010 raised €16 million through a Series A round.
"This substantial funding will build further value in both Imeglimin and Poxel.
The continued support from investors is a real testimony to the potential of
Imeglimin and our approach to treating diabetes," said Thomas Kuhn, CEO at
Poxel. "In addition to our proof of concept in mono- and in combination therapy,
the financing will support us in reinforcing Imeglimin's efficacy potential to
safely treat Type 2 diabetes."
Mr. Thierry Hercend, MD, PhD and Chairman of the board, said: "There is enormous
demand for new therapies to fight Type 2 diabetes. The excellent results we have
seen in the recent clinical trials lead us to the conclusion that Imeglimin has
great potential to be become a new anti-diabetic standard treatment."
Mr. Raphaël Wisniewski, Partner at EdRIP, stated: "Imeglimin is delivering on
all our expectations and proving Poxel as an excellent investment case. Only two
years after the series A financing round we have received impressive evidence of
significant data in Phase II trials. This new financing of €13 million provides
the company with a significant increase in Imeglimin's value and of course
Poxel's valuation."
About Type 2 Diabetes
Type 2 diabetes is the most common type of diabetes. It typically occurs in
adults, but is increasingly seen in children and adolescents. In Type 2
diabetes, the body is able to produce insulin but it is either not sufficient or
the body is not responding to its effects, leading to a build-up of glucose in
the blood. Type 2 diabetes is a major cause of both cardiovascular and kidney
diseases.
The number of people worldwide with Type 2 diabetes is rising rapidly. This rise
is associated with economic development, ageing populations, increasing
urbanization, dietary changes, reduced physical activity and changes in other
lifestyle patterns.
The International Diabetes Federation estimates that, in 2011, 366 million
people around the world had diabetes. This total is expected to rise to 552
million in 2030. Each year a further 7 million people develop diabetes. The
current market is dominated by few product classes and significant unmet needs
remain for both physicians and patients.
The worldwide pharmaceutical market for Type 2 diabetes, 60% of which is
represented by oral anti-diabetics, is expected to nearly double from $26
billion in 2011 to $48.8 billion in 2021.
About Poxel SA
Poxel, founded in 2009, is a biopharmaceutical company developing innovative
first-in-class drugs, with a primary focus on Type 2 diabetes. The company
develops drug candidates to clinical proof-of-concept before seeking
pharmaceutical industry partners. Poxel was spun out from Merck Serono. It
operates independently as a lean organization with strong in-house drug
development expertise.
Poxel's product pipeline consists of several first-in-class Type 2 diabetes
products, including Imeglimin in Phase II development. Recently, Imeglimin has
also shown significant clinical benefits in Type 2 diabetes, when added to
sitagliptin. The Phase II study achieved the primary and secondary endpoints.
Previously, Imeglimin has shown incremental efficacy as an add-on therapy to
metformin, in patients inadequately controlled by monotherapy. In addition, a
direct activator of AMPK is in preclinical development for the treatment of Type
2 diabetes.
About Imeglimin
Imeglimin is the first in a new chemical class of oral anti-diabetic agents, the
Glimins. Imeglimin acts on three main target organs involved in glucose
homeostasis: the liver, the muscle, and the pancreas with therefore a distinct
mode of action compared to existing treatments for Type 2 diabetes. Thanks also
to its great safety and tolerability profile, it appears as an excellent partner
to complement other treatments. Imeglimin phase 2a monotherapy results were
published in Diabetes, Obesity and Metabolism in April 2012. In October last
year, Poxel reported phase 2 results of Imeglimin as add-on therapy to metformin
in patients inadequately controlled with metformin monotherapy. This study
achieved its primary end-point of superiority in HbA1c reduction versus placebo
(p<0.001). Full study results were presented as a poster during the 73rd edition
of the American Diabetes Association meeting in Philadelphia last June and are
already accepted for publication in Diabetes Care. Recently, Imeglimin has also
shown significant clinical benefits in Type 2 diabetes, when added to
sitagliptin in sitagliptin-failing patients
About Edmond de Rothschild Investment Partners
Paris-based Edmond de Rothschild Investment Partners is dedicated to minority
investments into privately-owned companies. It has currently close to €1 billion
under management which is being invested primarily as life sciences venture
capital and growth capital.
Its Life Sciences Team of eight professionals brings together over 55 years of
experience in the Life Science industry and more than 100 years of private
equity and venture capital experience. The team has €355 million under
management through its Biodiscovery franchise.
Edmond de Rothschild Investment Partners is an independently managed affiliate
of La Compagnie Financière Edmond de Rothschild Banque. For more information
please visit: www.edrip.fr.
About CDC Entreprises / InnoBio
CDC Entreprises, an AMF-accredited fund management company and wholly-owned
subsidiary of the Caisse des Dépôts, invests directly and indirectly in
companies, from technological seed capital to small-scale mergers and
acquisitions, at both the national and regional levels. It manages investments
for France's FSI (Fonds Stratégique d'Investissement), for the Caisse des Dépôts
(now its second largest investor) and for other public and private institutions
in the small and medium size business sector. Its objective is to promote the
emergence of firms with long-term, stable growth by strengthening their equity
capital and supporting their development.
As such, CDC Entreprises manages on behalf of the State, under the Programme
d'Investissements d'Avenir, the Fonds National d'Amorçage, the SME component of
the Fonds national pour la Société Numérique, FSN SME and the Ecotechnologies
Fund.
CDC Entreprises is a major player in the equity financing of biotechnology
companies in France. It participates under the Programme FSI France
Investissement, in funding of most French sectorial funds dedicated to life
sciences. It is also the management company of InnoBio, a venture capital fund
(FCPR) of 139 million euros, subscribed by the FSI (37 percent) and major
pharmaceutical companies worldwide (Sanofi Aventis, GSK, Roche, Novartis,
Pfizer, Lilly, Ipsen, Takeda, Boehringer-Ingelheim). InnoBio operates on the
national territory. The main objective of the fund is to invest directly in
equity and quasi-equity investments in companies providing products and services
and innovative technology in the field of health. InnoBio is composed of a team
of industry expert investors, led by Laurent Arthaud.
About Omnes Capital
Omnes Capital is a major player in private equity, with a commitment to
financing SMEs. With €1.9 billion in assets under management, Omnes Capital
provides companies with the capital needed to finance their growth and with key
expertise in a number of areas: LBO & Expansion Capital, Venture Capital in
technology and life sciences, Renewable Energy, Secondary Funds of Funds, Co-
Investment.Omnes Capital, formerly Crédit Agricole Private Equity, was a
subsidiary of Crédit Agricole until March2012 when the company gained its
independence. Omnes Capital is a signatory to the United Nations Principles for
Responsible Investment (PRI).
Press contacts
Poxel SA MC Services AG Munich
Mr. Thomas Kuhn, CEO Mr. Raimund Gabriel
Phone: +33 4 37 37 20 10 Phone: +49 89 2102 280
Email: thomas.kuhn@poxelpharma.com Email: raimund.gabriel@mc-services.eu
Mrs. Pascale Malgouyres
Business Development Director
Phone: +33 4 37 37 20 10
Email: pascale.malgouyres@poxelpharma.com
Press release PDF:
http://hugin.info/143314/R/1665752/540494.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Poxel S.A. via Thomson Reuters ONE
[HUG#1665752]